{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T13:16:44Z","timestamp":1698844604205},"reference-count":22,"publisher":"Akademiai Kiado Zrt.","issue":"24","license":[{"start":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:00:00Z","timestamp":1623542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,6,13]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> Az \u00faj t\u00edpus\u00fa koronav\u00edrus (SARS-CoV-2) okozta pand\u00e9mia\n                    kezdet\u00e9n a szakmai k\u00f6zv\u00e9lem\u00e9ny \u00e1ltal\u00e1nos v\u00e9leked\u00e9se a Gaucher-k\u00f3ros betegek\n                    fokozott \u00e9rz\u00e9kenys\u00e9g\u00e9t vet\u00edtette el\u0151, magas morbidit\u00e1si \u00e9s mortalit\u00e1si\n                    mutat\u00f3kkal. Meglep\u0151 m\u00f3don azonban az eddigi, nagysz\u00e1m\u00fa betegen, az Egyes\u00fclt\n                    \u00c1llamokban, Eur\u00f3p\u00e1ban \u00e9s Izraelben v\u00e9gzett klinikai tanulm\u00e1nyok azt mutatj\u00e1k,\n                    hogy ezen s\u00falyos anyagcsere-betegs\u00e9gben sem a fert\u0151z\u00e9snek kitett betegek\n                    morbidit\u00e1si adatait, sem a ritk\u00e1n kialakult fert\u0151z\u00e9sek s\u00falyoss\u00e1g\u00e1t tekintve nem\n                    \u00e1ll fenn cs\u00f6kkent immunv\u00e9dekez\u00e9s a SARS-CoV-2-vel szemben. Ezen immunol\u00f3giai \u00e9s\n                    infektol\u00f3giai paradoxon lehets\u00e9ges magyar\u00e1zata, hogy a betegek makrof\u00e1gjaiban \u00e9s\n                    m\u00e1s sejtjeiben felhalmoz\u00f3d\u00f3 gl\u00fckocerebrozid gyullad\u00e1sos \u00e1llapotot tart fenn,\n                    amely h\u00e1tr\u00e1nyos a k\u00f3rokoz\u00f3 v\u00edrus intracellul\u00e1ris t\u00fal\u00e9l\u00e9se szempontj\u00e1b\u00f3l. A\n                    k\u00f6zlem\u00e9nyben \u00f6sszefoglaljuk a t\u00e9mak\u00f6rben eddig megjelent tanulm\u00e1nyok adatait, az\n                    \u00e1ltal\u00e1nos prevenci\u00f3val \u00e9s a vakcin\u00e1ci\u00f3val kapcsolatos aj\u00e1nl\u00e1sokat, \u00e9s kit\u00e9r\u00fcnk\n                    az 1-es t\u00edpus\u00fa interferonok (IFN\u03b1 \u00e9s IFN\u03c9) k\u00f6zelm\u00faltban megismert szerep\u00e9re a\n                    SARS-CoV-2-vel szembeni immunit\u00e1sban. Orv Hetil. 2021; 162(24): 938\u2013942.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> At the start of the pandemic caused by the novel\n                    coronavirus (SARS-CoV-2), the Gaucher disease community anticipated that\n                    infection with this emerging viral pathogen would be associated with high\n                    morbidity and mortality in individuals with this chronic metabolic disorder.\n                    Surprisingly, however, preliminary studies suggest that Gaucher disease does not\n                    confer a higher risk of severe, life-threatening effects of SARS-CoV-2\n                    infection, and no severe cases have been reported in large cohorts of patients\n                    from the United States, Europe and Israel. It is thought that the accumulation\n                    of glucocerebroside in the cells of Gaucher patients may promote immune\n                    tolerance rather than inflammation on exposure to SARS-CoV-2. We review here the\n                    current concepts of Gaucher disease and SARS-CoV-2 infection, focusing\n                    particularly on general prevention and vaccination. We also discuss the\n                    susceptibility to COVID-19 of patients with inborn errors of type 1 interferon\n                    (IFN\u03b1 and IFN\u03c9) immunity. Orv Hetil. 2021; 162(24): 938\u2013942.<\/jats:p>","DOI":"10.1556\/650.2021.32272","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:05:43Z","timestamp":1630404343000},"page":"938-942","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2-fert\u0151z\u00e9s \u00e9s COVID\u201319 Gaucher-k\u00f3ros betegekben: a v\u00e9d\u0151olt\u00e1s javallata"],"prefix":"10.1556","volume":"162","author":[{"given":"L\u00e1szl\u00f3","family":"Mar\u00f3di","sequence":"first","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, B\u0151r-, Nemik\u00f3rtani \u00e9s Dermatoonkol\u00f3giai Klinika, Primer Immundeficiencia Klinikai Egys\u00e9g \u00e9s Laborat\u00f3rium, Budapest, M\u00e1ria u. 41., 1085"},{"name":"2 Jelenlegi munkahely\/Present workplace: St. Giles Laboratory of Human Genetics of Infectious Diseases, The Rockefeller University, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"343","DOI":"10.15585\/mmwr.mm6912e2","article-title":"Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020","volume":"69","author":"Centers for Disease Prevention","year":"2020","unstructured":"1 Centers for Disease Prevention and Control. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. Morb Mortal Wkly Rep. 2020; 69: 343-346.","journal-title":"Morb Mortal Wkly Rep"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"2 Li","year":"2020","unstructured":"2 Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020; 92: 424-432.","journal-title":"J Med Virol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"3 Gheblawi","year":"2020","unstructured":"3 Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020; 126: 1456-1474.","journal-title":"Circ Res"},{"key":"ref3","unstructured":"4 Centers for Disease Control and Prevention. Coronavirus disease 2019. Available from: https:\/\/www.cdc.gov [accessed: April 4, 2021]."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Laczk\u00f3 D, Hogan MJ, Toulmin SA, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 2020; 53: 724-732.e7.","DOI":"10.1016\/j.immuni.2020.07.019"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"6 Sahin","year":"2020","unstructured":"6 Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020; 586: 594-599.","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 2021 Mar 25. . [Epub ahead of print]","DOI":"10.1038\/s41586-021-03470-x"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification","volume":"40","author":"8 Bousfiha","year":"2020","unstructured":"8 Bousfiha A, Jeddane L, Picard C, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020; 40: 66-81.","journal-title":"J Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Mar\u00f3di L. Interdisciplinary immunodeficiency: a novel approach to understanding primary immunodeficiency disorders. [Interdiszciplin\u00e1ris immundeficientia: \u00faj szeml\u00e9let a primer immunhi\u00e1ny-betegs\u00e9gek \u00e9rtelmez\u00e9s\u00e9ben.] Orv Hetil. 2018; 159: 895-897. [Hungarian]","DOI":"10.1556\/650.2018.31110"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"667727","DOI":"10.3389\/fimmu.2021.667727","article-title":"Advances in primary immunodeficiencies in Central-Eastern Europe","volume":"12","author":"10 Pac","year":"2021","unstructured":"10 Pac M, Casanova JL, Reisli I, et al. Advances in primary immunodeficiencies in Central-Eastern Europe. Front Immunol. 2021; 12: 667727.","journal-title":"Front Immunol"},{"key":"ref10","unstructured":"11 Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370: eabd4585."},{"key":"ref11","unstructured":"12 Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020; 370: eabd4570."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2265.2009.03740.x","article-title":"Novel sequence variation of AIRE and detection of interferon-\u03c9 antibodies in early infancy","volume":"72","author":"13 T\u00f3th","year":"2010","unstructured":"13 T\u00f3th B, Wolff AS, Hal\u00e1sz Z, et al. Novel sequence variation of AIRE and detection of interferon-\u03c9 antibodies in early infancy. Clin Endocrinol. 2010; 72: 641-647.","journal-title":"Clin Endocrinol"},{"key":"ref13","unstructured":"14 Zimran A, Elstein D. Gaucher disease and related lysosomal storage diseases. In: Lichtman M, Beutler E, Kipps TJ. (eds.) Williams' hematology. McGraw-Hill, New York, NY, 2016. Chapter 72."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bcmd.2007.02.005","article-title":"Genetic and clinical features of patients with Gaucher disease in Hungary","volume":"39","author":"15 Erd\u0151s","year":"2007","unstructured":"15 Erd\u0151s M, Hodanova K, Task\u00f3 S, et al. Genetic and clinical features of patients with Gaucher disease in Hungary. Blood Cells Mol Dis. 2007; 39: 119-123.","journal-title":"Blood Cells Mol Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1182\/blood.V86.12.4645.bloodjournal86124645","article-title":"Impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher disease: partial correction by enzyme replacement therapy","volume":"86","author":"16 Mar\u00f3di","year":"1995","unstructured":"16 Mar\u00f3di L, K\u00e1poszta R, T\u00f3th J, et al. Impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher disease: partial correction by enzyme replacement therapy. Blood 1995; 86: 4645-4649.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature21368","article-title":"Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease","volume":"543","author":"17 Pandey","year":"2017","unstructured":"17 Pandey MK, Burrow TA, Rani R, et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 2017; 543: 108-112.","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ymgme.2020.12.288","article-title":"Gaucher disease and SARS-CoV-2 infection: experience from 181 patients in New York","volume":"132","author":"18 Fierro","year":"2021","unstructured":"18 Fierro L, Nesheiwat N, Naik H, et al. Gaucher disease and SARS-CoV-2 infection: experience from 181 patients in New York. Mol Genet Metab. 2021; 132: 44-48.","journal-title":"Mol Genet Metab"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fimmu.2019.01143","article-title":"\u03b2-Glycosphingolipids as mediators of both inflammation and immune tolerance: a manifestation of randomness in biological systems","volume":"10","author":"19 Ilan","year":"2019","unstructured":"19 Ilan Y. \u03b2-Glycosphingolipids as mediators of both inflammation and immune tolerance: a manifestation of randomness in biological systems. Front Immunol. 2019; 10: 1143.","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ymgme.2021.02.005","article-title":"Gaucher disease in the COVID-19 pandemic environment: the good, the bad and the unknown","volume":"132","author":"20 Ginns","year":"2021","unstructured":"20 Ginns EI, Ryan E, Sidransky E. Gaucher disease in the COVID-19 pandemic environment: the good, the bad and the unknown. Mol Genet Metab. 2021; 132: 213-214.","journal-title":"Mol Genet Metab"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21 Andrade-Campos M, Escuder-Azuara B, de Frutos LL, et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher disease patients in Spain: time to reconsider home-based therapies? Blood Cells Mol Dis. 2020; 85: 102478.","DOI":"10.1016\/j.bcmd.2020.102478"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/imj.14894","article-title":"Impact of Gaucher disease on COVID-19","volume":"50","author":"22 Zimran","year":"2020","unstructured":"22 Zimran A, Szer J, Revel-Vilk S. Impact of Gaucher disease on COVID-19. Intern Med J. 2020; 50: 894-895.","journal-title":"Intern Med J"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/24\/article-p938.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/24\/article-p938.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T08:52:24Z","timestamp":1698742344000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/24\/article-p938.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,13]]},"references-count":22,"journal-issue":{"issue":"24"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32272","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,13]]}}}